Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9009268 | 0.84 | LMNA (0.36) | LMNATSHRMAPK1CA1CA2 | |
| SCHEMBL4589181 | 0.83 | LIMK1 (0.32) | — | |
| SCHEMBL5555230 | 0.81 | — | — | |
| SCHEMBL7607980 | 0.81 | LMNA (0.47) | LMNA | |
| SCHEMBL4588540 | 0.79 | — | — | |
| SCHEMBL4589954 | 0.76 | LMNA (0.32) | LMNA | |
| SCHEMBL4589205 | 0.76 | — | — | |
| SCHEMBL9238798 | 0.76 | TSHR (0.39) | LMNATSHRMAPK1 | |
| SCHEMBL5551345 | 0.74 | — | — | |
| SCHEMBL11387512 | 0.73 | TSHR (0.47) | LMNATSHRMAPK1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208140-B2 | Trimeric macrocyclic substituted benzene derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-04-24 | — | — | US | disclosed |
| US-20040265236-A1 | Trimeric macrocyclic substituted benzene derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040265236-A1 | Trimeric macrocyclic substituted benzene derivatives | BET1, TTI1, BRI3BP | LMNA 3086/4885TSHR 147/4885MAPK1 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.